Sign In
NewsRadar

Press release centre

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.
   

Past Press Releases - Bioxell S.p.A.

July 7, 2006
BioXell initiates Phase IIb trial of BXL628 in benign Prostatic Hyperplasia
BioXell S.p.A., an Italian biopharmaceutical company that is discovering and developing new treatments for urological disorders, today announced initiation of a Phase IIb clinical trial evaluating the efficacy of its lead compound BXL628
in Benign Prostatic Hyperplasia (BPH). More

May 11, 2006
BioXell Announces Phase II Results for Elocalcitol in Overactive Bladder
BioXell S.p.A. today reported clear efficacy of its lead compound, Elocalcitol (previously BXL628), in a Phase II study in Overactive Bladder (OAB). More

March 15, 2006
BioXell Raises Additional €10.5 million in Private Financing
BioXell today announced that it has raised €10.5 million in financing through an extension of the Series C round concluded in October, 2004. International life science investor TVM Capital led the financing, while BB Biotech, Index Ventures and Life Science Partners also increased their position in the Company. More

February 13, 2006
BioXell and Lay Line Genomics announce License Agreement
BioXell S.p.A. and Lay Line Genomics S.p.A. (LLG) today announced an exclusive, worldwide license agreement for the development of MNAC13, a novel humanized monoclonal antibody that binds to TrkA receptors, blocking the action of Nerve Growth Factor (NGF), a key mediator of pain. According to the agreement, BioXell will take MNAC13 through development and potential commercialisation, in exchange for an undisclosed upfront payment, milestones and royalties to LLG. More

January 24, 2006
BioXell promotes Meenu Chhabra to Chief Business Officer
BioXell SpA, the Italian biopharmaceutical company, announced the promotion of Meenu Chhabra to Chief Business Officer More

November 7, 2005
BioXell Initiates Phase IIa Trial of its Lead Compound
BioXell SpA, an Italian biopharmaceutical company focused on the discovery and development of new treatments for urological disorders, today announced the initiation of a Phase IIa trial to investigate the efficacy of its lead compound BXL628, a non-hypercalcemic Vitamin D Receptor (VDR) agonist, in chronic non-bacterial prostatitis (CP/CPPS)1. More

July 7, 2005
BioXell Initiates Phase IIb Trial of BXL628 in Benign Prostatic Hyperplasia
BioXell S.p.A., an Italian biopharmaceutical company that is
discovering and developing new treatments for urological disorders, today announced
initiation of a Phase IIb clinical trial evaluating the efficacy of its lead compound BXL628
in Benign Prostatic Hyperplasia (BPH). More

May 23, 2005
BioXell enters license agreement with Merck & Co. for TREM-1 product candidate and TREM platform
BioXell has signed an exclusive, worldwide license agreement with Merck & Co. for development of TREM related therapeutic and diagnostic products. More

January 13, 2005
BioXell Appoints Professor Peter van Brummelen to its Board of Directors
Milan, Italy, 13 January 2005 – BioXell SpA, a privately held Italian biopharmaceutical company, today announced the appointment of Professor Peter van Brummelen to its Board of Directors.
More

November 29, 2004
BioXell to commence phase IIa trial of its lead compound, BXL628, in Overactive Bladder
Milan, Italy, 29 November, 2004 – BioXell SpA, today announced the enrolment of the
first patients into its phase IIa program investigating the efficacy of BXL628 in Overactive
Bladder (OAB). The study will be randomized, double-blind, placebo controlled and will
involve 120 patients in 13 urology and gynaecology centres across Italy. The trial will be
coordinated by the Division of Urology at the San Raffaele Hospital in Milan. More

October 20, 2004
BioXell raises €23m in its Third Round of Private Financing
Milan, 20th October 2004: BioXell today announced that it has completed a private financing round raising €23m. The funding, led by the international life science investor BB BIOTECH, includes NIF Ventures from Japan and QVentures from Germany, in addition to Bioxell’s existing shareholders MPM Capital, Index Ventures, AlpInvest Partners, Life Science Partners and Investimenti Piccole Imprese.
More

September 27, 2004
BioXell Announces Positive Phase II Results for BXL628 in Benign Prostatic Hyperplasia
Milan, Italy, 27th September 2004 – BioXell SpA, the Italian biopharmaceutical company, today announced successful results in its Phase IIa trial of BXL-628 in patients with Benign Prostatic Hyperplasia (BPH). More

June 29, 2004
BioXell Acquires Rights from Roche to Develop BXL 628 in Additional Indications
Milan, Italy, 29th June 2004 –BioXell today announced that it has purchased additional indications from Roche for lead compound BXL 628 which, under the original agreement, was licensed to BioXell for benign prostatic hyperplasia (BPH), secondary hyperparathyroidism, transplant rejection and type I diabetes. More

Data


26,231
Tech investments
From our Online Data Service
16,945
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.